Glenn Goddard

Chief Financial Officer

US·SEC (Form 4)

Intellia Therapeutics, Inc.Agios Pharmaceuticals, Inc.

Cumul. flow

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (38 ops.)

€15.8M

Latest filing published 05 Mar 2024 for Intellia Therapeutics, Inc..

Filing timeline

BuySale

Glenn Goddard

Insider track record

Disclosed buys

Disclosed sells

Signal history

Glenn Goddard: trading record in brief

Filings by Glenn Goddard span 2 companies, the busiest being Agios Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. We count 91 filings; the first trade dates from 21 January 2014 and the latest from 1 March 2024.

No open-market purchase appears, only 38 sales worth €15.8M. Besides market trades, the filings include 4 share grants and 49 option exercises. 2024 to date brings no purchases and 1 sale.

On 5 March 2024 came the latest disclosure, a share grant in Intellia Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Glenn Goddard

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Intellia Therapeutics, Inc. (US)Agios Pharmaceuticals, Inc. (US)

Declarations91 total

◆
Glenn Goddard
EVP, Chief Financial OfficerExecutives1 Mar 2024Intellia Therapeutics, Inc.
0SEC
28,628 shares0Common StockSEC:0000950170-24-025901:0
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives3 Jan 2024Intellia Therapeutics, Inc.
158,053 USD39SEC
5,365 shares@ US$29.4621.1% of flowCommon StockSEC:0000950170-24-002511:0
◇
Glenn Goddard
EVP, Chief Financial OfficerExecutives1 Jan 2024Intellia Therapeutics, Inc.
0SEC
3,062 sharesCommon StockSEC:0000950170-24-001173:0
◆
Glenn Goddard
EVP, Chief Financial OfficerExecutives1 Mar 2023Intellia Therapeutics, Inc.
0SEC
27,484 shares0Common StockSEC:0001209191-23-015776:0
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives4 Jan 2023Intellia Therapeutics, Inc.
90,309 USD38SEC
2,427 shares@ US$37.2112.5% of flowCommon StockSEC:0001209191-23-002414:0
◇
Glenn Goddard
EVP, Chief Financial OfficerExecutives1 Jan 2023Intellia Therapeutics, Inc.
0SEC
3,062 sharesCommon StockSEC:0001209191-23-001490:0
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives1 Jan 2022Intellia Therapeutics, Inc.
113,699 USD34SEC
1,013 shares@ US$112.241.2% of flowCommon StockSEC:0001209191-22-015917:1
◆
Glenn Goddard
EVP, Chief Financial OfficerExecutives1 Mar 2022Intellia Therapeutics, Inc.
0SEC
12,720 shares0Common StockSEC:0001209191-22-015917:2
◇
Glenn Goddard
EVP, Chief Financial OfficerExecutives1 Jan 2022Intellia Therapeutics, Inc.
0SEC
3,062 sharesCommon StockSEC:0001209191-22-015917:0
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives7 Sept 2021Intellia Therapeutics, Inc.
627,178 USD38SEC
3,482 shares@ US$180.126.4% of flowCommon StockSEC:0001209191-21-055347:1
◇
Glenn Goddard
EVP, Chief Financial OfficerExecutives7 Sept 2021Intellia Therapeutics, Inc.
50,768 USD20SEC
3,482 shares@ US$14.586.3% of flowCommon StockSEC:0001209191-21-055347:0
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives30 Aug 2021Intellia Therapeutics, Inc.
107,867 USD37SEC
704 shares@ US$153.221.1% of flowCommon StockSEC:0001209191-21-054315:1
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives30 Aug 2021Intellia Therapeutics, Inc.
169,719 USD37SEC
1,100 shares@ US$154.291.8% of flowCommon StockSEC:0001209191-21-054315:2
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives30 Aug 2021Intellia Therapeutics, Inc.
263,993 USD37SEC
1,700 shares@ US$155.292.7% of flowCommon StockSEC:0001209191-21-054315:3
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives30 Aug 2021Intellia Therapeutics, Inc.
46,830 USD37SEC
300 shares@ US$156.100.5% of flowCommon StockSEC:0001209191-21-054315:4
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives30 Aug 2021Intellia Therapeutics, Inc.
78,036 USD37SEC
496 shares@ US$157.330.8% of flowCommon StockSEC:0001209191-21-054315:5
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives30 Aug 2021Intellia Therapeutics, Inc.
47,526 USD37SEC
300 shares@ US$158.420.5% of flowCommon StockSEC:0001209191-21-054315:6
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives30 Aug 2021Intellia Therapeutics, Inc.
47,859 USD37SEC
300 shares@ US$159.530.5% of flowCommon StockSEC:0001209191-21-054315:7
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives30 Aug 2021Intellia Therapeutics, Inc.
48,252 USD37SEC
300 shares@ US$160.840.5% of flowCommon StockSEC:0001209191-21-054315:8
◇
Glenn Goddard
EVP, Chief Financial OfficerExecutives31 Aug 2021Intellia Therapeutics, Inc.
442,882 USD19SEC
22,983 shares@ US$19.274.6% of flowCommon StockSEC:0001209191-21-054315:9
◇
Glenn Goddard
EVP, Chief Financial OfficerExecutives31 Aug 2021Intellia Therapeutics, Inc.
26,492 USD19SEC
1,817 shares@ US$14.580.3% of flowCommon StockSEC:0001209191-21-054315:10
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives31 Aug 2021Intellia Therapeutics, Inc.
4M USD41SEC
24,800 shares@ US$160.2241.0% of flowCommon StockSEC:0001209191-21-054315:11
◇
Glenn Goddard
EVP, Chief Financial OfficerExecutives30 Aug 2021Intellia Therapeutics, Inc.
100,204 USD20SEC
5,200 shares@ US$19.2712.4% of flowCommon StockSEC:0001209191-21-054315:0
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives5 Aug 2021Intellia Therapeutics, Inc.
1M USD33SEC
9,902 shares@ US$150.6515.3% of flowCommon StockSEC:0001209191-21-050225:1
▼
Glenn Goddard
EVP, Chief Financial OfficerExecutives5 Aug 2021Intellia Therapeutics, Inc.
1M USD32SEC
9,568 shares@ US$151.4114.9% of flowCommon StockSEC:0001209191-21-050225:2

25 of 91 declarations

Glenn Goddard

Insider track record

Glenn Goddard: trading record in brief

Companies and markets linked to Glenn Goddard

Similar companies

Related executives